Krystal Biotech
A USA-based company focused on developing and commercializing genetic medicines for patients with rare diseases.
The company’s wide-ranging pipeline is based on its proprietary redosable HSV vector.
In May 2023, Vyjuvek was approved by the US FDA for the treatment of dystrophic epidermolysis bullosa (DEB). Vyjuvek is a non-invasive, topical, redosable gene therapy designed to treat DEB at the molecular level. This made it the first FDA-approved treatment for a rare, devastating skin disease.
Latest Krystal Biotech News & Features
30 November 2021
Today's issue
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze